2,726 reports of this reaction
6.1% of all PIPERACILLIN SODIUM,TAZOBACTAM SODIUM reports
#1 most reported adverse reaction
DRUG INEFFECTIVE is the #1 most commonly reported adverse reaction for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, manufactured by Fresenius Kabi USA, LLC. There are 2,726 FDA adverse event reports linking PIPERACILLIN SODIUM,TAZOBACTAM SODIUM to DRUG INEFFECTIVE. This represents approximately 6.1% of all 44,977 adverse event reports for this drug.
Patients taking PIPERACILLIN SODIUM,TAZOBACTAM SODIUM who experience drug ineffective should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG INEFFECTIVE is moderately reported among PIPERACILLIN SODIUM,TAZOBACTAM SODIUM users, representing a notable but not dominant share of adverse events.
In addition to drug ineffective, the following adverse reactions have been reported for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM:
The following drugs have also been linked to drug ineffective in FDA adverse event reports:
DRUG INEFFECTIVE has been reported as an adverse event in 2,726 FDA reports for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG INEFFECTIVE accounts for approximately 6.1% of all adverse event reports for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, making it one of the most commonly reported side effect.
If you experience drug ineffective while taking PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.